聯交所對寶沙發展(01069.HK)兩名前董事作出紀律行動
聯交所公布對寶沙發展(01069.HK)兩名前董事的紀律行動。聯交所向該公司前執行董事路薇及前非執行董事劉志坤發出董事不適合性聲明並公開譴責他們二人。董事不適合性聲明是指聯交所認為,該兩名前董事不適合擔任公司或其任何附屬公司的董事或高級管理層成員。
上市委員會裁定,相關董事沒有配合上市科的調查而違反了其《董事承諾》,因而構成違反《上市規則》。即使相關董事已辭任該公司董事,他們仍然有責任提供聯交所合理要求的資料;及相關董事違反其《董事承諾》的情況嚴重,其行為亦屬嚴重及/或一再違反《上市規則》所述的董事職責。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.